Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Halozyme Therapeutics's Sloan Ratio for the quarter that ended in Mar. 2024 was 0.39%.
As of Mar. 2024, Halozyme Therapeutics has a Sloan Ratio of 0.39%, indicating the company is in the safe zone and there is no funny business with accruals.
Halozyme Therapeutics Sloan Ratio % Historical Data
The historical data trend for Halozyme Therapeutics's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Halozyme Therapeutics's Sloan Ratio %
For the Biotechnology subindustry, Halozyme Therapeutics's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Halozyme Therapeutics's Sloan Ratio % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Halozyme Therapeutics's Sloan Ratio % falls into.
Halozyme Therapeutics Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Halozyme Therapeutics's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Halozyme Therapeutics's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was 74.754 (Jun. 2023 ) + 81.837 (Sep. 2023 ) + 85.388 (Dec. 2023 ) + 76.823 (Mar. 2024 ) = $318.8 Mil.
Halozyme Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was 66.842 (Jun. 2023 ) + 132.411 (Sep. 2023 ) + 102.354 (Dec. 2023 ) + 129.427 (Mar. 2024 ) = $431.0 Mil.
Halozyme Therapeutics's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was 54.994 (Jun. 2023 ) + -83.45 (Sep. 2023 ) + -8.291 (Dec. 2023 ) + -82.681 (Mar. 2024 ) = $-119.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Halozyme Therapeutics (NAS:HALO) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Mar. 2024, Halozyme Therapeutics has a Sloan Ratio of 0.39%, indicating the company is in the safe zone and there is no funny business with accruals.
Halozyme Therapeutics Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Halozyme Therapeutics's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Halozyme Therapeutics (Halozyme Therapeutics) Business Description
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HALO has been successfully added to your 